90 related articles for article (PubMed ID: 27476943)
1. In Vitro Enhancement of Carvedilol Glucuronidation by Amiodarone-Mediated Altered Protein Binding in Incubation Mixture of Human Liver Microsomes with Bovine Serum Albumin.
Sekimoto M; Takamori T; Nakamura S; Taguchi M
Biol Pharm Bull; 2016; 39(8):1359-63. PubMed ID: 27476943
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory and stimulative effects of amiodarone on metabolism of carvedilol in human liver microsomes.
Horiuchi I; Kato Y; Nakamura A; Ishida K; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2010; 33(4):717-20. PubMed ID: 20410613
[TBL] [Abstract][Full Text] [Related]
3. Stereoselective glucuronidation of carvedilol in human liver and intestinal microsomes.
Hanioka N; Tanaka S; Moriguchi Y; Narimatsu S
Pharmacology; 2012; 90(3-4):117-24. PubMed ID: 22814440
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes.
Ishida K; Taira S; Morishita H; Kayano Y; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2008 Jun; 31(6):1297-300. PubMed ID: 18520073
[TBL] [Abstract][Full Text] [Related]
5. Mutual inhibition between carvedilol enantiomers during racemate glucuronidation mediated by human liver and intestinal microsomes.
Takekuma Y; Yagisawa K; Sugawara M
Biol Pharm Bull; 2012; 35(2):151-63. PubMed ID: 22293344
[TBL] [Abstract][Full Text] [Related]
6. Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol.
Ohno A; Saito Y; Hanioka N; Jinno H; Saeki M; Ando M; Ozawa S; Sawada J
Drug Metab Dispos; 2004 Feb; 32(2):235-9. PubMed ID: 14744946
[TBL] [Abstract][Full Text] [Related]
7. The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities.
Rowland A; Knights KM; Mackenzie PI; Miners JO
Drug Metab Dispos; 2008 Jun; 36(6):1056-62. PubMed ID: 18362158
[TBL] [Abstract][Full Text] [Related]
8. Stereoselective glucuronidation of carvedilol by Chinese liver microsomes.
You LY; Yu CN; Xie SG; Chen SQ; Zeng S
J Zhejiang Univ Sci B; 2007 Oct; 8(10):756-64. PubMed ID: 17910120
[TBL] [Abstract][Full Text] [Related]
9. Effect of chronic hypoxic hypoxia on oxidation and glucuronidation of carvedilol in rats.
Yamaura S; Fukao M; Ishida K; Taguchi M; Hashimoto Y
Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):53-9. PubMed ID: 23739952
[TBL] [Abstract][Full Text] [Related]
10. Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism.
Nardotto GHB; Coelho EB; Paiva CE; Lanchote VL
J Clin Pharmacol; 2017 Jun; 57(6):760-769. PubMed ID: 28114735
[TBL] [Abstract][Full Text] [Related]
11. Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol.
Fukumoto K; Kobayashi T; Komamura K; Kamakura S; Kitakaze M; Ueno K
Drug Metab Pharmacokinet; 2005 Dec; 20(6):423-7. PubMed ID: 16415527
[TBL] [Abstract][Full Text] [Related]
12. Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform.
Ma L; Sun J; Peng Y; Zhang R; Shao F; Hu X; Zhu J; Wang X; Cheng X; Zhu Y; Wan P; Feng D; Wu H; Wang G
Drug Metab Dispos; 2012 Apr; 40(4):734-41. PubMed ID: 22238289
[TBL] [Abstract][Full Text] [Related]
13. Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity.
Takekuma Y; Takenaka T; Yamazaki K; Ueno K; Sugawara M
Biol Pharm Bull; 2007 Nov; 30(11):2146-53. PubMed ID: 17978490
[TBL] [Abstract][Full Text] [Related]
14. Trans-3'-hydroxycotinine O- and N-glucuronidations in human liver microsomes.
Yamanaka H; Nakajima M; Katoh M; Kanoh A; Tamura O; Ishibashi H; Yokoi T
Drug Metab Dispos; 2005 Jan; 33(1):23-30. PubMed ID: 15470160
[TBL] [Abstract][Full Text] [Related]
15. Stereoselective effects of (R)- and (S)-carvedilol in humans.
Stoschitzky K; Koshucharova G; Lercher P; Maier R; Sakotnik A; Klein W; Liebmann PM; Lindner W
Chirality; 2001 Jul; 13(7):342-6. PubMed ID: 11400186
[TBL] [Abstract][Full Text] [Related]
16. Stereoselective glucuronidation of formoterol by human liver microsomes.
Zhang M; Fawcett JP; Kennedy JM; Shaw JP
Br J Clin Pharmacol; 2000 Feb; 49(2):152-7. PubMed ID: 10671910
[TBL] [Abstract][Full Text] [Related]
17. Hepatic UDP-glucuronosyltransferase is responsible for eslicarbazepine glucuronidation.
Loureiro AI; Fernandes-Lopes C; Bonifácio MJ; Wright LC; Soares-da-Silva P
Drug Metab Dispos; 2011 Sep; 39(9):1486-94. PubMed ID: 21673130
[TBL] [Abstract][Full Text] [Related]
18. Diethylstilbestrol can effectively accelerate estradiol-17-O-glucuronidation, while potently inhibiting estradiol-3-O-glucuronidation.
Zhu L; Xiao L; Xia Y; Zhou K; Wang H; Huang M; Ge G; Wu Y; Wu G; Yang L
Toxicol Appl Pharmacol; 2015 Mar; 283(2):109-16. PubMed ID: 25596428
[TBL] [Abstract][Full Text] [Related]
19. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes.
Kilford PJ; Stringer R; Sohal B; Houston JB; Galetin A
Drug Metab Dispos; 2009 Jan; 37(1):82-9. PubMed ID: 18832476
[TBL] [Abstract][Full Text] [Related]
20. Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver.
Mano Y; Usui T; Kamimura H
Drug Metab Dispos; 2007 Jul; 35(7):1182-7. PubMed ID: 17446261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
